Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial ( Ridker et al., 2017a ) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events—and, surprisingly, lung cancer.

中文翻译：

---

CANTOS迎来了针对血管保护的炎性靶向新演算-也许更多

尽管将炎症与动脉粥样硬化血栓形成的病理生物学联系起来的基础科学不胜枚举，但仍缺乏表明抗炎药物治疗对心血管有益的具体临床证据。CANTOS试验（Ridker等人，2017a）现在提供了第一个大规模的概念证明，即靶向炎性体可以减少心血管事件，以及令人惊讶的是肺癌。